efficaci
method
avoid
infect
pathogen
virus
immun
individu
prophylact
vaccin
howev
virus
vaccin
avail
antivir
drug
block
replic
viru
infect
individu
therefor
great
import
battl
viru
infect
ideal
drug
induc
strong
specif
inhibit
viru
replic
without
affect
cellular
process
type
drug
remain
fiction
zamecnik
stephenson
report
sequencespecif
inhibit
rou
sarcoma
viru
replic
antisens
dna
oligonucleotid
zamecnik
stephenson
paper
subsequ
report
sequencespecif
knockdown
gene
antisens
technolog
made
big
impress
scientif
commun
compar
current
rnai
boom
howev
develop
antisensebas
therapeut
stutter
almost
came
stop
problem
toxic
oligonucleotid
instabl
serum
problem
deliveri
right
target
cell
new
gener
nucleic
acidbas
antivir
compound
subsequ
develop
ribozym
dnazym
decoy
rna
face
similar
problem
problem
could
solv
use
chemic
modifi
nucleic
acid
instead
normal
dnarna
oligonucleotid
exampl
modif
phosphorothio
ps
dna
omethylrna
ome
increas
affin
oligonucleotid
target
sequenc
increas
serum
stabil
see
fig
new
hope
nucleic
acidbas
therapeut
came
elbashir
cowork
show
synthet
small
interf
rna
sirna
induc
sequencespecif
knockdown
gene
mammalian
cell
without
trigger
interferon
respons
elbashir
et
al
rnai
immedi
recogn
potenti
power
new
tool
combat
varieti
virus
inde
profound
inhibit
report
mani
import
human
pathogen
virus
sever
potenti
antivir
sirna
compound
current
test
clinic
trial
despit
promis
data
becom
increasingli
clear
problem
earlier
encount
antisens
drug
also
appli
rnaibas
therapeut
although
rnaimedi
silenc
highli
sequencespecif
therapeut
sirna
caus
unwant
silenc
cellular
mrna
fedorov
et
al
jackson
et
al
kleinman
et
al
addit
synthet
sirna
also
subject
degrad
vivo
nucleas
activ
besid
side
effect
instabl
effici
specif
deliveri
rnai
induc
target
cell
still
requir
optim
summar
current
statu
nucleic
acidbas
antivir
therapeut
focu
antivir
strategi
use
antisens
rnai
technolog
addit
antivir
ribozym
aptam
discuss
briefli
focu
recent
studi
gene
therapi
approach
deliveri
system
subject
chapter
book
antisens
technolog
base
sequencespecif
bind
antisens
dna
oligonucleotid
complementari
sequenc
target
mrna
van
aerschot
bind
target
rna
oligonucleotid
block
translat
via
steric
hindranc
elong
ribosom
induc
rna
cleavag
activ
rnase
h
enzym
specif
recogn
dnarna
duplex
although
antisens
technolog
induc
profound
sequencespecif
inhibit
gene
express
set
major
problem
includ
instabl
deliveri
unwant
side
effect
oligonucleotid
chemic
modif
oligonucleotid
found
improv
efficaci
fig
first
gener
chemic
modif
design
enhanc
nucleas
resist
oligonucleotid
serum
stein
et
al
ps
modif
oxygen
atom
dna
backbon
replac
sulfur
atom
wide
use
advantag
psmodifi
oligonucleotid
allow
rnase
h
cleavag
target
sequenc
disadvantag
ps
modif
introduc
neg
charg
caus
nonspecif
interact
molecul
exampl
cellular
protein
result
psmodifi
oligonucleotid
notori
induc
sever
side
effect
toxic
cell
wellknown
exampl
antivir
psmodifi
oligonucleotid
vitraven
treatment
cytomegaloviru
cmv
induc
retin
aid
patient
inhibit
express
viral
protein
major
immediateearli
transcript
unit
vitraven
studi
group
vitraven
antisensebas
drug
receiv
fda
approv
use
clinic
although
vitraven
provid
mark
reduct
diseas
sever
compound
current
wide
use
mainli
aid
patient
antiretrovir
therapi
rare
develop
cmvinduc
retin
second
gener
oligonucleotid
base
modif
sugar
ring
exampl
ome
omethoxyethyl
moe
modif
fig
increas
stabil
oligonucleotid
affin
target
mrna
compar
psmodifi
oligonucleotid
contrast
ps
modif
ome
moemodifi
oligonucleotid
allow
cleavag
rnase
h
rather
block
translat
via
steric
hindranc
ribosom
translat
optim
activ
oligonucleotid
target
sequenc
near
translat
initi
site
ome
modif
also
use
combin
ps
modif
socal
gapmer
central
nucleotid
carri
ps
modif
flank
nucleotid
ome
modif
monia
et
al
approach
combin
benefit
first
second
gener
modif
exampl
second
generationmodifi
antivir
oligonucleotid
develop
hybridon
current
discontinu
gapmer
ome
modifi
flank
ps
modifi
central
sequenc
turner
et
al
third
gener
oligonucleotid
dna
rna
analogu
extens
modif
phosphat
backbon
sugar
ring
exampl
peptid
nucleic
acid
pna
backbon
replac
peptid
linker
morpholino
phosphoroamid
mf
lock
nucleic
acid
lna
fig
iversen
larsen
et
al
petersen
wengel
modif
provid
improv
nucleas
resist
target
affin
addit
pna
mf
modif
allow
enhanc
cellular
uptak
combin
benefit
third
gener
modif
use
combin
unmodifi
residu
chimaer
gapmer
lna
modif
wide
use
variou
applic
introduc
cmethylen
bridg
lock
ribos
endo
conform
lock
conform
result
strong
increas
affin
target
mrna
petersen
wengel
lna
modif
report
caus
less
toxic
side
effect
compar
first
second
gener
modif
wahlestedt
et
al
howev
lnamodifi
oligonucleotid
recent
shown
induc
profound
toxic
hepatocyt
mice
swayz
et
al
despit
intens
effort
test
differ
chemic
modif
far
littl
success
develop
potent
safe
antivir
mchutchison
et
al
test
group
patient
patient
respond
treatment
reduct
hcv
viral
load
research
conclud
studi
need
evalu
novel
agent
side
effect
previous
isi
pharmaceut
report
log
reduct
plasma
viru
patient
chronic
hcv
infect
use
wwwisispharmcom
warfield
et
al
report
profound
inhibit
ebola
viru
mice
rhesu
macaqu
use
antisens
mf
oligonucleotid
warfield
et
al
combin
sever
oligonucleotid
target
mrna
rna
polymeras
protect
anim
therapeut
prophylact
modifi
oligonucleotid
protect
macaqu
lethal
ebola
viru
infect
similarli
mf
oligonucleotid
recent
found
profoundli
inhibit
murin
hepat
coronaviru
treatment
protect
mice
normal
lethal
viral
challeng
indic
toxic
effect
burrer
et
al
differ
antivir
approach
use
intracellular
express
unmodifi
antisens
molecul
correspond
viral
sequenc
intracellular
immun
approach
may
requir
gene
therapi
protocol
deliv
antivir
transgen
phase
clinic
trial
levin
et
al
use
intracellularli
express
antisens
transcript
inhibit
replic
advantag
use
extend
antisens
sequenc
multipl
viral
site
target
simultan
levin
et
al
condit
replic
lentivir
vector
use
transduc
cell
ex
vivo
intracellular
express
antisens
sequenc
envelop
gene
modifi
cell
infus
back
patient
appar
well
toler
patient
one
five
patient
show
sustain
decreas
viral
load
levin
et
al
altern
short
antisens
molecul
sequenc
gag
gene
shown
inhibit
viru
replic
transduc
cem
cell
gu
et
al
ribozym
repres
class
natur
rna
catalys
rna
cleavag
ligat
reaction
well
peptid
bond
format
case
reaction
selfprocess
event
take
place
sequencespecif
manner
found
howev
ribozym
design
specif
cleav
rna
molecul
tran
modif
substrat
recognit
domain
sequenc
specif
multipl
turnov
catalyt
properti
ribozym
extens
studi
potenti
therapeut
peracchi
nine
class
ribozym
hammerhead
hairpin
ribozym
receiv
great
deal
attent
ribozym
rel
small
nucleotid
direct
cleavag
singlestrand
target
rna
mani
ribozym
use
therapeut
applic
improv
vitro
select
procedur
activ
molecul
select
partial
random
sequenc
vitro
select
also
gener
dnazym
structur
function
resembl
ribozym
dna
instead
rna
backbon
santoro
joyc
dnazym
catalyt
activ
similar
ribozym
stabl
vivo
therapeut
ribozym
use
synthet
rna
transfect
cell
intracellularli
express
rna
unmodifi
ribozym
rapidli
degrad
serum
synthet
ribozym
requir
chemic
modif
extend
half
life
improv
therapeut
potenti
ribozym
gonzalez
carmona
et
al
jakobsen
et
al
antivir
ribozym
extens
test
gene
therapi
set
studi
ribozym
place
control
suitabl
promot
insert
vector
transduc
target
cell
ribozym
studi
sever
clinic
trial
macpherson
et
al
test
antitat
ribozym
phase
clinic
trial
macpherson
et
al
preclin
studi
ribozym
shown
decreas
replic
virusinduc
pathogen
cell
line
peripher
blood
tlymphocyt
clinic
trial
tlymphocyt
transduc
ex
vivo
use
retrovir
vector
express
ribozym
transduc
cell
given
back
hivposit
patient
gene
therapi
found
safe
shown
inhibit
replic
li
cowork
use
ribozym
combin
sirna
decoy
rna
inhibit
replic
li
et
al
ribozym
target
toward
mrna
cellular
protein
function
essenti
coreceptor
entri
decoy
viral
tar
rna
hairpin
structur
suppos
bind
viral
tat
protein
cellular
cofactor
need
viral
gene
express
hematopoiet
progenitor
cell
also
transduc
retrovir
vector
express
ribozym
cell
differenti
normal
matur
macrophag
show
signific
resist
viral
infect
ribozym
use
combin
tatrev
sirna
tar
decoy
transduc
cell
show
longterm
viral
resist
vitro
transduc
hematopoiet
stem
cell
develop
normal
cell
scidhu
mice
cell
abl
resist
infect
ex
vivo
anderson
et
al
contrast
nucleic
acidbas
antivir
strategi
decoy
rna
small
rnadna
aptam
act
via
specif
bind
viral
target
protein
rather
viral
rna
interact
decoy
target
protein
prevent
activ
henc
block
viru
replic
jame
tar
decoy
describ
earlier
wellknown
exampl
anoth
decoy
rna
inhibit
correspond
rev
respons
element
rre
interact
rre
viral
rev
protein
requir
transport
singl
unsplic
viral
rna
nucleu
cytoplasm
overexpress
rre
decoy
sequest
rev
protein
therebi
block
nuclear
export
viral
rna
thu
viru
replic
bahner
et
al
rre
decoy
earlier
test
phase
clinic
trial
stem
cell
transduc
ex
vivo
retrovir
vector
express
rna
inhibitor
kohn
et
al
evid
express
decoy
affect
cell
function
also
detect
chang
subject
plasma
level
besid
overexpress
decoy
rna
resembl
natur
viral
rna
motif
also
interest
use
artifici
small
nucleic
acid
aptam
high
affin
certain
target
protein
aptam
identifi
larg
random
pool
sequenc
repetit
round
select
bind
highest
affin
target
protein
jame
earli
target
aptam
develop
viral
polymeras
exampl
potent
aptam
select
inhibit
revers
transcriptas
rt
hcv
rna
polymeras
bellecav
et
al
burk
et
al
tuerk
et
al
aptam
similar
viral
sequenc
indic
high
affin
bind
aptam
necessarili
analogu
natur
substrat
shown
rt
aptam
potent
inhibit
rt
enzym
multipl
subtyp
suggest
aptam
provid
broad
protect
held
et
al
howev
natur
resist
viru
strain
exist
aptam
mean
antivir
use
combin
inhibitor
rnai
recent
ad
list
nucleic
acidbas
therapeut
eukaryot
cell
rnai
play
import
role
regul
gene
express
via
microrna
mirna
small
noncod
rna
express
primari
mirna
primirna
process
cellular
protein
drosha
dicer
matur
mirna
nucleotid
fig
mammal
mirna
typic
direct
translat
inhibit
cellular
mrna
bear
complementari
sequenc
utr
grimson
et
al
rnai
also
propos
play
role
cellular
defens
virus
silenc
transpos
element
gener
virusspecif
sirna
bennass
et
al
soifer
et
al
triboulet
et
al
yang
kazazian
shrnamir
dicer
primirna
fig
rnai
induc
use
antivir
strategi
gener
rnai
induc
either
transfect
synthet
sirna
cell
stabl
transient
intracellular
express
doublestrand
sirna
precursor
shrna
eshrna
lhrna
primirna
transcript
nucleu
shrna
lhrna
eshrna
export
cytoplasm
subsequ
dice
matur
sirna
primirna
modifi
encod
antivir
sirna
first
undergo
cleavag
drosha
export
cytoplasm
antivir
premirna
also
call
shrnamir
process
dicer
matur
mirna
load
antisens
strand
sirnasmirna
risc
complex
target
cleav
viral
transcript
bear
complementari
sequenc
mechan
involv
small
rna
tam
et
al
watanab
et
al
mirna
sirna
load
rnainduc
silenc
complex
risc
target
rna
respect
translat
repress
destruct
fig
although
antivir
function
rnai
well
establish
plant
insect
nematod
still
debat
whether
rnai
similar
role
mammal
circumstanti
evid
grow
support
idea
andersson
et
al
bennass
et
al
cullen
grimson
et
al
soifer
et
al
tam
et
al
voinnet
watanab
et
al
watanab
et
al
yang
kazazian
discoveri
exogen
deliv
synthet
sirna
intracellularli
express
short
hairpin
rna
shrna
trigger
gene
silenc
mammalian
cell
made
rnai
power
techniqu
gener
genet
knockdown
brummelkamp
et
al
elbashir
et
al
also
allow
develop
rnaibas
therapeut
prevent
viru
transmiss
treatment
viru
replic
overview
therapeut
strategi
use
induc
antivir
rnai
respons
shown
fig
synthet
sirna
duplex
use
induc
rnai
gener
nucleotid
long
overhang
model
natur
dicer
cleavag
product
antisens
strand
guid
antivir
sirna
load
risc
complex
target
viral
rna
sequencespecif
manner
altern
transient
transfect
plasmid
express
antivir
shrna
also
use
induc
rnai
shrna
typic
base
pair
long
small
apic
loop
termin
uu
overhang
shrna
usual
express
nucleu
control
polymeras
iii
promot
transloc
cytoplasm
shrna
process
cytoplasm
dicer
function
sirna
technolog
shrnainduc
rnai
significantli
improv
use
shrna
variant
close
resembl
natur
mirna
second
gener
shrna
shrnamir
design
use
increas
knowledg
biochemistri
rnai
mechan
mirna
biogenesi
shrnamir
express
larger
transcript
control
polymeras
ii
promot
contain
bulg
nucleotid
intern
loop
present
priand
premirna
boden
et
al
du
et
al
liu
et
al
silva
et
al
compar
shrna
shrnamir
show
significantli
increas
activ
anoth
possibl
induc
rnai
intracellular
express
long
hairpin
rna
lhrna
akashi
et
al
konstantinova
et
al
liu
et
al
nishitsuji
et
al
watanab
et
al
weinberg
et
al
contrast
transfect
dsrna
larger
bp
intracellular
express
seem
induc
interferon
respons
effici
inhibit
lhrna
report
hcv
hbv
besid
convent
lhrna
extendedshrna
eshrna
also
success
use
trigger
potent
rnai
respons
eshrna
encod
individu
effect
sirna
stack
form
lhrna
structur
potenti
advantag
lhrna
eshrna
gener
multipl
sirna
singl
precursor
molecul
may
prevent
viral
escap
similar
antisens
oligonucleotid
synthet
sirna
rel
instabl
vivo
due
degrad
nucleas
activ
sirna
half
life
must
increas
effect
antivir
therapeut
would
allow
treatment
infrequ
administr
small
amount
sirna
also
increas
prophylact
potenti
sirna
case
influenza
viru
individu
risk
could
treat
stabil
antivir
sirna
season
epidem
thu
avoid
infect
chemic
modif
earlier
use
antisens
compound
success
use
increas
half
life
sirna
vivo
retain
activ
morrissey
et
al
b
rana
exampl
introduc
pslinkag
end
render
sirna
resist
exonucleas
activ
wherea
ome
modif
give
resist
endonucleas
howev
modif
increas
stabil
neg
effect
sirna
activ
czauderna
et
al
modif
end
result
loss
sirna
activ
emphas
import
modif
antisens
passeng
strand
stabil
sirna
without
neg
effect
activ
sens
guid
strand
lna
modif
dramat
increas
potenc
sirna
vitro
vivo
without
toxic
elmen
et
al
numer
research
group
studi
rnai
altern
method
block
use
transient
transfect
synthet
sirna
stabli
express
shrna
arrighi
et
al
da
et
al
jacqu
et
al
lee
et
al
martinez
et
al
novina
et
al
qin
et
al
surabhi
gaynor
ter
brake
et
al
westerhout
et
al
longterm
viru
suppress
rnai
gene
therapi
approach
perhap
best
suit
target
virus
caus
chronic
infect
lenti
retro
adenoassoci
viru
aav
vector
use
stabli
transduc
cell
construct
express
antivir
shrna
result
cellular
resist
viru
transduct
hematopoiet
stem
cell
rnai
construct
ex
vivo
graft
cell
back
patient
result
resist
cell
popul
might
reconstitut
patient
immun
system
berkhout
see
also
chapter
prolong
vitro
cultur
resist
cell
result
emerg
viral
escap
variant
longer
target
sirna
rnai
escap
variant
contain
point
mutat
delet
within
sirna
target
sequenc
da
et
al
addit
escap
viru
describ
mutat
outsid
target
sequenc
mutat
trigger
escap
induc
conform
chang
local
rna
secondari
structur
render
target
sequenc
inaccess
risc
westerhout
et
al
escap
rnai
also
report
polioviru
hepat
viru
hbv
hcv
boden
et
al
da
et
al
gitlin
et
al
kusov
et
al
ter
brake
berkhout
von
eij
et
al
westerhout
et
al
wilson
richardson
wu
et
al
combin
result
show
singl
sirna
therapi
suffici
obtain
longterm
inhibit
viru
replic
escap
rnai
reminisc
evolut
drug
resist
variant
patient
antiretrovir
therapi
combin
use
multipl
drug
highli
activ
antiretrovir
therapi
haart
perman
block
viru
replic
without
emerg
resist
variant
similarli
combin
express
multipl
sirna
would
requir
persist
block
viru
replic
combinatori
approach
ideal
target
viral
sequenc
essenti
well
conserv
among
differ
viru
strain
emerg
escap
variant
delay
cell
express
two
sirna
compar
cell
express
singl
sirna
cell
express
four
potent
sirna
viral
escap
observ
lhrna
also
use
induc
rnai
respons
konstantinova
et
al
konstantinova
et
al
liu
et
al
lhrna
process
multipl
effect
sirna
thu
prevent
chanc
viral
escap
although
lhrna
shown
effect
inhibit
replic
current
data
abil
prevent
viral
escap
use
multipl
sirna
lhrna
take
account
increas
danger
side
effect
due
interfer
cellular
mirna
process
function
prevent
viral
escap
rnai
altern
strategi
target
host
factor
essenti
viral
replic
howev
host
factor
target
without
affect
host
cell
viabil
arrighi
et
al
liu
et
al
ping
et
al
qin
et
al
zhou
et
al
well
known
exampl
coreceptor
coreceptor
import
viru
entri
yet
mutat
gene
affect
fit
host
liu
et
al
samson
et
al
recent
brass
et
al
publish
largescal
sirna
screen
identifi
host
factor
requir
replic
brass
et
al
hivdepend
factor
identifi
may
repres
potenti
target
therapi
despit
avail
effect
hbv
vaccin
viru
still
major
health
problem
approxim
million
person
infect
worldwid
hepat
infect
liver
caus
varieti
rna
virus
hepat
viru
hepat
b
viru
hepat
c
viru
rnai
use
inhibit
hbv
replic
vitro
vivo
eli
et
al
hamasaki
et
al
klein
et
al
konishi
et
al
weinberg
et
al
ying
et
al
hbv
member
hepadnavirida
genom
doublestrand
circular
dna
synthet
sirna
shrna
express
construct
show
potent
inhibit
hbv
replic
mice
chen
et
al
chen
et
al
giladi
et
al
mccaffrey
et
al
morrissey
et
al
shin
et
al
wu
et
al
xuan
et
al
ying
et
al
rnaibas
therapi
need
provid
long
period
hbv
caus
chronic
infect
liver
transduct
hepatocyt
vivo
vector
express
antihbv
shrna
could
provid
longterm
protect
chen
et
al
inde
demonstr
longterm
inhibit
hbv
mice
transduc
aav
vector
deliv
shrna
inhibitor
hbv
dna
mrna
protein
level
reduc
liver
transgen
mice
wherea
amount
circul
viru
drop
log
viru
inhibit
still
appar
day
vector
administr
chen
et
al
addit
lhrna
shrnamir
could
effici
inhibit
hbv
replic
vitro
mice
eli
et
al
weinberg
et
al
respiratori
virus
perhap
best
suit
target
rnaibas
therapeut
upper
airway
lung
rel
easi
reach
target
tissu
alreadi
sever
studi
report
therapeut
effect
anim
model
clinic
trial
exampl
sirna
influenza
viru
found
reduc
viru
titer
lung
infect
mice
sirna
administ
hydrodynam
intraven
inject
ge
et
al
similarli
viru
titer
reduc
mice
given
dna
vector
either
intraven
intranas
express
antivir
shrna
ge
et
al
moreov
reduc
virusinduc
mortal
score
treat
mice
even
sirna
deliv
viru
infect
suggest
sirna
act
prophylact
manner
treatment
establish
infect
anoth
studi
synthet
sirna
also
protect
mice
lethal
influenza
viru
challeng
tompkin
et
al
sirna
treatment
induc
broad
protect
pathogen
avian
influenza
virus
serotyp
anoth
respiratori
viru
rnai
therapeut
develop
respiratori
syncyti
viru
rsv
fact
rsv
first
viru
rnaimedi
inhibit
demonstr
bitko
barik
synthet
sirna
current
enter
phase
ii
clinic
trial
rsv
belong
paramyxovirida
envelop
nonseg
negativestrand
rna
viru
rsv
major
caus
respiratori
ill
upper
lower
respiratori
tract
typic
lead
common
coldlik
symptom
case
especi
young
children
lead
seriou
ill
bronchiol
pneumonia
mice
replic
rsv
also
human
parainfluenza
viru
could
block
synthet
sirna
bitko
et
al
synthet
sirna
intranas
administr
plasmid
express
shrna
result
signific
decreas
rsv
load
zhang
et
al
similar
sirnainduc
inhibit
influenza
viru
sirna
rsv
effect
infect
rsv
alnylam
present
result
phase
clinic
trial
lead
sirna
drug
candid
http
wwwalnylamcom
drug
found
safe
well
toler
administ
intranas
two
phase
clinic
studi
devincenzo
et
al
phase
ii
clinic
trial
natur
infect
rsv
patient
initi
april
expect
advanc
pediatr
patient
popul
second
half
rnai
sever
acut
respiratori
syndrom
coronaviru
sarscoronaviru
coronavirus
also
studi
extens
sirna
plasmidderiv
shrna
effect
block
viru
replic
cell
cultur
infect
et
al
lu
et
al
ni
et
al
pyrc
et
al
wang
et
al
wu
et
al
zhang
et
al
potent
sirna
inhibitor
sarscoronaviru
spike
pol
mrna
also
test
efficaci
safeti
rhesu
macaqu
sar
model
sirna
administ
intranas
prophylact
concurr
viral
challeng
earli
postexposur
li
et
al
similar
mice
studi
antiinfluenza
sirna
antirsv
sirna
prophylact
therapeut
effect
observ
sirna
treatment
caus
signific
reduct
viral
rna
level
sarslik
symptom
lung
histopatholog
combin
find
suggest
low
dosag
inhal
intraven
administ
sirna
shrna
plasmid
may
provid
easi
effici
basi
prophylaxi
respiratori
virus
certain
situat
exampl
pandem
influenza
threat
antivir
therapi
alreadi
infect
individu
rnai
highli
specif
tool
induc
gene
knockdown
howev
studi
show
high
express
sirnashrna
induc
interferon
respons
unwant
side
effect
bridg
et
al
jackson
linsley
cellular
transcript
contain
partial
complementar
sirna
also
target
rnaimedi
knockdown
fedorov
et
al
jackson
et
al
offtarget
effect
great
concern
develop
safe
rnaibas
antivir
impact
cell
viabil
jackson
linsley
high
concentr
sirnashrna
may
also
interfer
cellular
mirna
process
function
problem
caus
fact
shrna
process
use
cellular
pathway
mirna
process
particular
requir
nuclear
export
stabil
mirna
found
limit
factor
rnai
pathway
could
satur
exogen
shrna
extrem
case
side
effect
sever
consequ
illustr
mice
die
treatment
aav
vector
overexpress
shrna
liver
grimm
et
al
studi
also
show
shrnathreshold
toxic
limit
knowledg
cellular
mirna
function
underestim
impact
shrna
process
moder
express
highli
activ
shrna
essenti
develop
safe
rnai
therapeut
candid
shrnasirna
inhibitor
screen
offtarget
effect
induc
promot
use
regul
shrna
express
avoid
offtarget
effect
avoid
toxic
offtarget
effect
antivir
rnai
therapeut
virus
ideal
target
transient
local
low
dosag
could
realiz
acut
respiratori
viral
infect
treatment
chronic
viral
infect
may
requir
durabl
gene
therapi
approach
eleg
strategi
reduc
potenti
offtarget
effect
sirna
passeng
strand
use
socal
small
intern
segment
interf
rna
sisirna
bramsen
et
al
sisirna
compos
intact
antisens
strand
complement
two
shorter
nt
sens
strand
segment
natur
passeng
strand
inact
wherea
antisens
strand
still
effici
induc
potent
rnai
respons
deliveri
sirna
right
target
cell
also
limit
impact
potenti
offtarget
effect
progress
made
use
nanoparticl
load
sirna
particl
rang
nm
diamet
use
load
high
concentr
sirna
protect
environ
nanoparticl
target
specif
cell
tissu
decor
surfac
ligand
target
specif
cell
surfac
receptor
ligand
transferrin
antibodi
folat
integrintarget
peptid
alreadi
success
use
target
sirna
particl
cell
bear
correspond
receptor
guo
et
al
hulieskovan
et
al
schiffel
et
al
tan
et
al
result
promis
contribut
develop
safe
effici
sirna
deliveri
system
develop
nucleic
acidbas
therapeut
straightforward
research
initi
anticip
stabil
toxic
specif
deliveri
compound
continu
challeng
issu
need
optim
recent
year
research
come
intric
solut
greatli
improv
efficaci
potenti
antisens
ribozym
well
rnaibas
therapeut
clinic
trial
type
nucleic
acidbas
therapeut
underway
far
data
sever
trial
studi
anim
model
look
promis
particular
therapi
trigger
rnai
pathway
howev
histori
shown
compound
well
phase
phase
ii
clinic
trial
may
still
fail
phase
iii
strike
exampl
nonspecif
suppress
angiogenesi
sirna
via
tolllik
receptor
kleinman
et
al
becom
clear
near
futur
compound
make
new
class
antivir
therapeut
